| __timestamp | HUTCHMED (China) Limited | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 72049000 | 14400000 |
| Thursday, January 1, 2015 | 110777000 | 33800000 |
| Friday, January 1, 2016 | 156328000 | 35900000 |
| Sunday, January 1, 2017 | 175820000 | 1254000 |
| Monday, January 1, 2018 | 143944000 | 4889000 |
| Tuesday, January 1, 2019 | 160152000 | 7400000 |
| Wednesday, January 1, 2020 | 188519000 | 10100000 |
| Friday, January 1, 2021 | 258234000 | 14300000 |
| Saturday, January 1, 2022 | 311103000 | 23200000 |
| Sunday, January 1, 2023 | 384447000 | 39700000 |
| Monday, January 1, 2024 | 34000000 |
Unleashing insights
In the ever-evolving landscape of biopharmaceuticals, understanding cost dynamics is crucial. Over the past decade, HUTCHMED (China) Limited and Neurocrine Biosciences, Inc. have showcased contrasting trends in their cost of revenue. From 2014 to 2023, HUTCHMED's cost of revenue surged by over 430%, reflecting its aggressive expansion and scaling efforts in the competitive Chinese market. In contrast, Neurocrine Biosciences, Inc. experienced a more modest increase of approximately 175%, indicative of its strategic focus on niche markets and innovative therapies.
By 2023, HUTCHMED's cost of revenue reached nearly 10 times that of Neurocrine, highlighting the divergent paths these companies have taken. This data not only underscores the varying business strategies but also offers insights into the broader industry trends, where scale and specialization play pivotal roles in shaping financial outcomes.
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and HUTCHMED (China) Limited's Expenses
Cost of Revenue: Key Insights for Biogen Inc. and HUTCHMED (China) Limited
Analyzing Cost of Revenue: United Therapeutics Corporation and Neurocrine Biosciences, Inc.
Cost of Revenue Trends: United Therapeutics Corporation vs HUTCHMED (China) Limited
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Incyte Corporation
Cost Insights: Breaking Down Neurocrine Biosciences, Inc. and Dr. Reddy's Laboratories Limited's Expenses
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and ADMA Biologics, Inc.
Analyzing Cost of Revenue: Neurocrine Biosciences, Inc. and Travere Therapeutics, Inc.
Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Ionis Pharmaceuticals, Inc. and HUTCHMED (China) Limited
PTC Therapeutics, Inc. vs HUTCHMED (China) Limited: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: HUTCHMED (China) Limited vs Viridian Therapeutics, Inc.